![](https://investorshub.advfn.com/uicon/825665.png?cb=1657717173)
Thursday, January 26, 2023 1:39:57 AM
Regencell has become a leader in the field, spearheading the efforts to alleviate the unmet medical needs of millions of people around the world. Through their research and development programs, the company is working to develop treatments for ADHD and ASD patients, as well as for infectious diseases that affect the human immune systems.
Recently, the company has been gaining attention for its clinical trials, specifically the EARTH Trial, which has shown that RGC-COV19TM is an effective formula for the alleviation and elimination of COVID-19 symptoms within 6 days. This not only helps to reduce the symptoms for patients, but also reduces the risk of hospitalizations and death. These results have shown the effectiveness of TCM and alternative medicine in a hyper-modern and tech-driven world.
Yat-Gai Au believes that it is crucial to have the right team in place in order to remain true to the company's values and continue to head in the right direction. The Regencell team is dedicated to ensuring that their services and products are effective, safe, and useful for their patients.
In addition to their commitment to TCM research and development, Regencell is also focused on the commercialization of their products. The company recently went public through an Initial Public Offering on the stock market, and since then, the company's shares have grown by approximately 247.31%.
Despite turbulent market conditions, Regencell is comfortably poised for growth. Yat-Gai Au and the majority of shareholders are insider investors, and have recently invested more than $5.9 million in the company, showing their confidence in the future of Regencell Bioscience
https://www.ibtimes.com/regencell-ceo-shares-his-vision-insights-aims-change-way-patients-are-treated-3600337
Recent RGC News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/20/2024 01:13:05 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/02/2024 11:04:03 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/15/2023 11:09:52 AM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/27/2023 08:15:39 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM